Study #2022-0147
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR T-cell Therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Loncastuximab Tesirine
Description
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Large B-cell Lymphoma, Lymphoma
Study phase:
Phase II
Physician name:
Paolo Strati
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-737-0154
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.